In HR+ breast cancer, samuraciclib is effective both alone, and when combined with hormonal therapy, in breast cancer models, and that CDK7 inhibition would be effective even after resistance develops to CDK4/6 inhibitors9. Here, CDK4 is linked to breast carcinoma.